X-ZELL™ is a global start-up specialising in rare cell detection technology.
Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC).
X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology.
By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology,
X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making.
More information on www.x-zell.com and @XZELLInc
